Phase 1 Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BMS-906024 in Subjects With Advanced Solid Tumors
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Number of subjects with adverse events as a measure of safety and tolerability.
Weekly assessments until study discontinuation due to disease progression or unacceptable adverse event as well as an assessment 30 day after treatment discontinuation with an average time on study expected to be <1 year.
Yes
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb
United States: Food and Drug Administration
CA216-001
NCT01292655
March 2011
February 2015
Name | Location |
---|---|
Wayne State University | Detroit, Michigan 48202 |
Local Institution | Austin, Texas |
Local Institution | Jackson, Mississippi |
Anthony El-Khoueiry, Md | Los Angeles, California 90033 |